机构:[1]Capital Med Univ, Beijing Tongren Hosp, Dept Hematol, Beijing 100730, Peoples R China临床科室血液内科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[2]Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing 100730, Peoples R China[3]Capital Med Univ, Beijing Tongren Hosp, Beijing 100730, Peoples R China首都医科大学附属北京同仁医院首都医科大学附属同仁医院[4]Peking Union Med Coll Hosp, Dept Breast Surg, Beijing 100032, Peoples R China[5]Capital Med Univ, Beijing Tongren Hosp, Dept Otolaryngol Head & Neck Surg, Beijing 100730, Peoples R China临床科室耳鼻咽喉-头颈外科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[6]Beijing Inst Otolaryngol, Beijing Key Lab Nasal Dis, Beijing 100730, Peoples R China研究所耳鼻咽喉科研究所首都医科大学附属北京同仁医院首都医科大学附属同仁医院
To date, much progress has been made in early-stage extranodal NK/T-cell lymphoma (ENKTCL), and risk-adapted therapy with radiotherapy (RT) alone for the low-risk group and RT combined with asparaginase-based chemotherapy (CT) for the high-risk group yields favorable outcomes. However, optimal treatment strategies have not been defined yet for advanced-stage ENKTCL. Historically, ENKTCL responded poorly to conventional anthracycline-based chemotherapy probably because of inherent multidrug resistance (MDR). The fact that ENKTCL cells lack asparagine synthetase (ASNS) activity warranted the use of L-asparaginase or pegaspargase as frontline chemotherapies. Even though, due to high mortality of the disease, approximately 50% patients failing the frontline therapy arrived at dismal clinical outcomes with a median progression-free survival (PFS) less than 8 months. As distinctive molecular and biological subgroups are increasingly discovered within the disease entity of ENKTCL, novel targeted therapies and immunotherapy are of the urgent need for those heterogeneous subgroups. In this review, we sought to summarize the preclinical and clinical results of 6 categories of promising targeted therapy and immunotherapy for the treatment of ENKTCL, including monoclonal antibodies, immune checkpoint inhibitors, small-molecular inhibitors, epigenetic therapy, immunomodulatory drugs, and adoptive T-cell therapy, and these might change the landscape of treatment for ENKTCL in the near future.
基金:
National Natural Science Foundation of China (81873450) and the
Open Research Fund from Beijing Advanced Innovation Center for Big
Data-Based Precision Medicine, Beijing Tongren Hospital, Beihang
University & Capital Medical University (grant No. BHTR-KFJJ202009) to Liang Wang
第一作者机构:[1]Capital Med Univ, Beijing Tongren Hosp, Dept Hematol, Beijing 100730, Peoples R China[2]Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing 100730, Peoples R China[3]Capital Med Univ, Beijing Tongren Hosp, Beijing 100730, Peoples R China[*1]Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
共同第一作者:
通讯作者:
通讯机构:[1]Capital Med Univ, Beijing Tongren Hosp, Dept Hematol, Beijing 100730, Peoples R China[2]Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing 100730, Peoples R China[3]Capital Med Univ, Beijing Tongren Hosp, Beijing 100730, Peoples R China[*1]Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
推荐引用方式(GB/T 7714):
Wang Liang,Li Lin-Rong,Zhang Luo,et al.The landscape of new drugs in extranodal NK/T-cell lymphoma[J].CANCER TREATMENT REVIEWS.2020,89:doi:10.1016/j.ctrv.2020.102065.
APA:
Wang, Liang,Li, Lin-Rong,Zhang, Luo&Wang, Jing-Wen.(2020).The landscape of new drugs in extranodal NK/T-cell lymphoma.CANCER TREATMENT REVIEWS,89,
MLA:
Wang, Liang,et al."The landscape of new drugs in extranodal NK/T-cell lymphoma".CANCER TREATMENT REVIEWS 89.(2020)